The United Kingdom and the United States have hammered out a key bilateral deal that will keep zero duties on UK pharmaceutical shipments being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the public health system. This pledge guarantees that duties on these vital exports will be held at zero for a period of the next three years.
This agreement is in response to recent statements to significantly raise import taxes on branded drug imports, with increases discussed reaching one hundred percent.
"This arrangement with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to transatlantic medicine commerce," a release said.
Economic Importance
Pharmaceuticals constitute one of the UK's largest exports to the US, which is easily the largest destination for major companies like GSK and AstraZeneca.
Trade data show that in the year prior to September, the UK sold drugs worth £11.1bn to the US. This figure accounted for 17.4% of total UK exports in that span.
"This agreement secures employment, stimulates investment and facilitates the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Key NHS Changes
The pact entails several key changes from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds exceeded 20%.
Broader Context
The deal takes place against a ongoing dispute between the drug companies and the British authorities over drug pricing and regulatory access.
This friction were intensified by claims that American patients were paying several times more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS must invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its resources over the past decade.
